Rational design and protein engineering of growth factors for regenerative medicine and tissue engineering

Biochemical Society Transactions

Volumn 37, Issue 4, 2009, Pages 717-721

  Moss, Andrew J ^a   Sharma, Shikha ^a   Brindle, Nicholas P J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Growth factor; Protein engineering; Receptor tyrosine kinase (RTK)

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; COLLAGEN BINDING PROTEIN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; VASCULOTROPIN; SIGNAL PEPTIDE;

CELL PH; CONFERENCE PAPER; LIGAND BINDING; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TRANSPORT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TISSUE REGENERATION; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; METHODOLOGY; REGENERATIVE MEDICINE; REVIEW; SYNTHESIS; THEORETICAL MODEL;

ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, THEORETICAL; PROTEIN ENGINEERING; REGENERATIVE MEDICINE; TISSUE ENGINEERING;

EID: 70349308148     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0370717     Document Type: Conference Paper

References (40)

1. Chen, R.R. and Mooney, D.J. (2003) Polymeric growth factor delivery strategies for tissue engineering. Pharm. Res. 20, 1103-1112
2. Takeshita, S., Zheng, L.P., Brogi, E., Kearney, M., Pu, L.-Q., Bunting, S., Ferrara, N., Symes, J.F. and Isner, J.M. (1994) Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments re-vascularization of a rabbit ischemic hind limb model. J. Clin. Invest. 93, 662-670
3. Henry, T.D., Annex, B.H., McKendall, G.R., Azrin, M.A., Lopez, J.J., Giordano, F.J., Shah, P.K., Willerson, J.T., Benza, R.L., Berman, D.S. et al. (2003) The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107, 1359-1365
4. Chan, G. and Mooney, D.J. (2008) New materials for tissue engineering: towards greater control over the biological response. Trends Biotechnol. 26, 382-392
5. Ullrich, A. and Schlessinger, J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203-212
6. Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103, 211-225
7. Hubbard, S.R. (2007) Receptor tyrosine kinases: mechanisms of activation and signaling. Curr. Opin. Cell Biol. 19, 117-123
8. Davis, S., Papadopoulos, N., Aldrich, T.H., Maisonpierre, P.C., Huang, T., Kovac, L., Xu, A., Leidich, R., Radziejewska, E., Rafique, A. et al. (2003) Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 10, 38-44
9. Ballinger, M.D., Shyamala, V., Forrest, L.D., Deuter-Reinhard, M., Doyle, L.V., Wang, J.X., Panganiban-Lustan, L., Stratton, J.R., Apell, G., Winter, J.A. et al. (1999) Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat. Biotechnol. 17, 1199-1204
10. Schaffer, L., Brissette, R.E., Spetzler, J.C., Pillutla, R.C., Ostergaard, S., Lennick, M., Brandt, J., Fletcher, P.W., Danielsen, G.M., Hsiao, K.-C. et al. (2003) Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc. Natl. Acad. Sci. U.S.A. 100, 4435-4439
11. Cho, C.-H., Kammerer, R.A., Lee, H.J., Steinmetz, M.O., Ryu, Y.S., Lee, S.H., Yasunaga, K., Kim, K.-T., Kim, I., Choi, H.-H. et al. (2004) COMP-Ang1: A designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc. Natl. Acad. Sci. U.S.A. 101, 5547-5552
12. Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N. et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60
13. Sil, D., Lee, J.B., Luo, D., Holowka, D. and Baird, B. (2007) Trivalent ligands with rigid DNA spacers reveal structural requirements for IgE receptor signaling in RBL mast cells. ACS Chem. Biol. 2, 674-684
14. Nishi, N., Matsushita, O., Yuube, K., Miyanaka, H., Okabe, A. and Wada, F. (1998) Collagen-binding growth factors: production and characterization of functional fusion proteins having a collagen-binding domain. Proc. Natl. Acad. Sci. U.S.A. 95, 7018-7023
15. Ishikawa, T., Eguchi, M., Wada, M., Iwami, Y., Tono, K., Iwaguro, H., Masuda, H., Tamaki, T. and Asahara, T. (2006) Establishment of a functionally active collagen-binding vascular endothelial growth factor fusion protein in situ. Arterioscler. Thromb. Vasc. Biol. 26, 1998-2004
16. Kitajima, T., Terai, H. and Ito, Y. (2007) A fusion protein of hepatocyte growth factor for immobilization to collagen. Biomaterials 28, 1989-1997
17. Nakaji-Hirabayashi, T., Kato, K., Arima, Y. and Iwata, H. (2007) Oriented immobilization of epidermal growth factor onto culture substrates for the selective expansion of neural stem cells. Biomaterials 28, 3517-3529
18. Ogiwara, K., Nagaoka, M., Cho, C.S. and Akaike, T. (2005) Construction of a novel extracellular matrix using a new genetically engineered epidermal growth factor fused to IgG-Fc. Biotechnol. Lett. 27, 1633-1637
19. Backer, M.V., Patel, V., Jehning, B.T., Claffey, K.P. and Backer, J.M. (2006) Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials 27, 5452-5458
20. Folkman, J., Klagsburn, M., Sasse, J., Wadzinski, M., Ingber, D. and Vlodavsky, I. (1988) A heparin-binding angiogenic protein, basic fibroblast growth factor, is stored within basement membrane. Am. J. Pathol. 130, 393-400
21. Park, J.E., Keller, G.A. and Ferrara, N. (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317-1326
22. Sakiyama-Elbert, S.E., Panitch, A. and Hubbell, J.A. (2001) Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J. 15, 1300-1302
23. Ehrbar, M., Djonov, V.G., Schnell, C., Tschanz, S.A., Martiny-Baron, G., Schenk, U., Wood, J., Burri, P.H., Hubbell, J.A. and Zisch, A.H. (2004) Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res. 94, 1124-1132
24. Ito, Y. (2008) Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 4, 45-56
25. Bromberg, L. and Salvati, Jr, L. (1999) Bioactive surfaces via immobilization of self-assembling polymers onto hydrophobic materials. Bioconjugate Chem. 10, 678-686
26. Ito, Y., Chen, G., Imanishi, Y., Morooka, T., Nishida, E., Okabayashi, Y. and Kasuga, M. (2001) Differential control of cellular gene expression by diffusible and non-diffusible EGF. J. Biochem. 129, 733-737
27. Kim, Y.S., Bhandari, R., Cochran, J.R., Kuriyan, J. and Wittrup, K.D. (2006) Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins 62, 1026-1035
28. Lippow, S.M. and Tidor, B. (2007) Progress in computational protein design. Curr. Opin. Biotechnol. 18, 305-311
29. Zakrzewska, M., Krowarsch, D., Wiedlocha, A. and Otlewski, J. (2004) Design of fully active FGF-1 variants with increased stability. Protein Eng. Des. Sel. 17, 603-611
30. Lehmann, M. and Wyss, M. (2001) Engineering proteins for thermostability: the use of sequence alignments versus rational design and directed evolution. Curr. Opin. Biotechnol. 12, 371-375
31. Sieber, V., Pluckthun, A. and Schmid, F.X. (1998) Selecting proteins with improved stability by a phage-based method. Nat. Biotechnol. 16, 955-960
32. Tangri, S., Mothe, B.R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R. et al. (2005) Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174, 3187-3196
33. Sinclair, A.M. and Elliott, S. (2005) Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94, 1626-1635
34. Levin, A.M. and Weiss, G.A. (2006) Optimizing the affinity and specificity of proteins with molecular display. Mol. Biosyst. 2, 49-57
35. Pearce, Jr, K.H., Cunningham, B.C., Fuh, G., Teeri, T. and Wells, J.A. (1999) Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity. Biochemistry 38, 81-89
36. Haugh, J.M. (2004) Mathematical model of human growth hormone (hGH)-stimulated cell proliferation explains the efficacy of hGH variants as receptor agonists or antagonists. Biotechnol. Prog. 20, 1337-1344
37. Rao, B.M., Lauffenburger, D.A. and Wittrup, K.D. (2005) Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat. Biotechnol. 23, 191-194
38. Mukherjee, S., Ghosh, R.N. and Maxfield, F.R. (1997) Endocytosis. Physiol. Rev. 77, 759-803
39. Sarkar, C.A., Lowenhaupt, K., Horan, T., Boone, T.C., Tidor, B. and Lauffenburger, D.A. (2002) Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat. Biotechnol. 20, 908-913
40. Reddy, C.C., Niyogi, S.K., Wells, A., Wiley, H.S. and Lauffenburger, D.A. (1996) Engineering epidermal growth factor for enhanced mitogenic potency. Nat. Biotechnol. 14, 1696-1699